PDS0203

**PDS0203** is an investigational, recombinant protein-subunit COVID-19 vaccine developed by PDS Biotech with Farmacore Biotechnology. It combines a SARS-CoV-2 spike-derived recombinant protein antigen with PDS Biotech's Versamune T-cell-activating platform, aiming to induce neutralizing antibodies as well as durable virus-specific CD4 and CD8 T-cell responses. PDS Biotech currently lists the program as preclinical; Farmacore held Latin American development rights, and Blanver was selected to manufacture and commercialize the candidate in Latin America. ([pdsbiotech.com](https://www.pdsbiotech.com/index.php/pipeline/infectious-disease/pds0203))

Other names

Versamune-CoV2-FCVersamune-CoV-2-FCVersamune-CoV 2-FCVersamune-CoV-2Versamune-CoV2Versamune-CoV 2